Telomere length and mortality following a diagnosis of ovarian cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 11, 2014, Pages 2603-2606

  Kotsopoulos, Joanne ^a,b   Prescott, Jennifer ^c,d   De Vivo, Immaculata ^c,d   Fan, Isabel ^e   Mclaughlin, John ^e   Rosen, Barry ^f,g   Risch, Harvey ^h   Sun, Ping ^a   Narod, Steven A ^a,b  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HARVARD MEDICAL SCHOOL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e MOUNT SINAI HOSPITAL   (Canada)

^f PRINCESS MARGARET HOSPITAL   (Canada)

^g UNIVERSITY OF TORONTO   (Canada)

^h YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; ASSAY; CANADA; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; LEUKOCYTE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OVARY CANCER; POLYMERASE CHAIN REACTION; POPULATION BASED CASE CONTROL STUDY; QUANTITATIVE ANALYSIS; TELOMERE HOMEOSTASIS; GENETICS; MIDDLE AGED; MORTALITY; OVARIAN NEOPLASMS; TELOMERE; TELOMERE SHORTENING;

FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; TELOMERE; TELOMERE SHORTENING;

EID: 84920201322     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-14-0885     Document Type: Article

References (8)

1. Prescott J, Wentzensen IM, Savage SA, De Vivo I. Epidemiologic evidence for a role of telomere dysfunction in cancer etiology. Mutt Res 2012;730:75-84.
2. Kuhn E, Meeker A, Wang TL, Sehdev AS, Kurman RJ, Shih Ie M. Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis. Am J Surg Pathol 2010;34:829-36.
3. Idei T, Sakamoto H, Yamamoto T. Terminal restriction fragments of telomere are detectable in plasma and their length correlates with clinical status of ovarian cancer patients. J Int Med Res 2002;30:244-50.
4. Mirabello L, Garcia-Closas M, Cawthon R, Lissowska J, Brinton LA, Peplonska B, et al. Leukocyte telomere length in a population-based case-control study of ovarian cancer: a pilot study. Cancer Causes Control 2010;21:77-82.
5. Narod SA, Moody JR, Rosen B, Fan I, Risch HA, Sun P, et al. Estimating survival rates after ovarian cancer among women tested for BRCA1 and BRCA2 mutations. Clin Genet 2013;83:232-7.
6. De Vivo I, Prescott J, Wong JY, Kraft P, Hankinson SE, Hunter DJ. A prospective study of relative telomere length and postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 2009;18:1152-6.
7. Terry KL, Tworoger SS, Vitonis AF, Wong J, Titus-Ernstoff L, De Vivo I, et al. Telomere length and genetic variation in telomere maintenance genes in relation to ovarian cancer risk. Cancer Epidemiol Biomarkers Prev 2012;21:504-12.
8. Chene G, Tchirkov A, Pierre-Eymard E, Dauplat J, Raoelfils I, Cayre A, et al. Early telomere shortening and genomic instability in tubo-ovarian preneoplastic lesions. Clin Cancer Res 2013;19:2873-82.